Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fluoroquinolones Get New Safety Labeling, But Not A REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.


Related Content

Second EMA Public Hearing To Focus On Quinolone, Fluoroquinolone Side Effects
Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says
FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes
Fluoroquinolones Need REMS With Communication Plan, AdCom Says
Fluoroquinolones: Is Another FDA Safety Step Needed?
Fluoroquinolones To Get “Better” But Not Necessarily Stronger Warning On Nerve Damage
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts